JP2002512947A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002512947A5 JP2002512947A5 JP2000545506A JP2000545506A JP2002512947A5 JP 2002512947 A5 JP2002512947 A5 JP 2002512947A5 JP 2000545506 A JP2000545506 A JP 2000545506A JP 2000545506 A JP2000545506 A JP 2000545506A JP 2002512947 A5 JP2002512947 A5 JP 2002512947A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- fviii
- colloidal particles
- protein
- particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002245 particle Substances 0.000 description 26
- 239000008194 pharmaceutical composition Substances 0.000 description 24
- 102000001690 Factor VIII Human genes 0.000 description 17
- 108010054218 Factor VIII Proteins 0.000 description 17
- 229960000301 factor viii Drugs 0.000 description 14
- 150000002632 lipids Chemical class 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 229920000642 polymer Polymers 0.000 description 7
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 229920001477 hydrophilic polymer Polymers 0.000 description 5
- 230000007935 neutral effect Effects 0.000 description 5
- 238000007911 parenteral administration Methods 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 229940105778 coagulation factor viii Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
- 208000031220 Hemophilia Diseases 0.000 description 2
- 208000009292 Hemophilia A Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL12422498 | 1998-04-27 | ||
| IL124224 | 1998-04-27 | ||
| PCT/IL1999/000217 WO1999055306A1 (en) | 1998-04-27 | 1999-04-23 | Pharmaceutical composition comprising factor viii and neutral liposomes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002512947A JP2002512947A (ja) | 2002-05-08 |
| JP2002512947A5 true JP2002512947A5 (cg-RX-API-DMAC10.html) | 2006-01-05 |
| JP4545928B2 JP4545928B2 (ja) | 2010-09-15 |
Family
ID=11071435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000545506A Expired - Fee Related JP4545928B2 (ja) | 1998-04-27 | 1999-04-23 | 第ｖｉｉｉ因子及び中性リポソームを含有する薬学的組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US6593294B1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP1079805B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP4545928B2 (cg-RX-API-DMAC10.html) |
| AT (1) | ATE283034T1 (cg-RX-API-DMAC10.html) |
| AU (1) | AU747391B2 (cg-RX-API-DMAC10.html) |
| BR (1) | BR9909978A (cg-RX-API-DMAC10.html) |
| CA (1) | CA2329768C (cg-RX-API-DMAC10.html) |
| DE (1) | DE69922189T2 (cg-RX-API-DMAC10.html) |
| ES (1) | ES2233036T3 (cg-RX-API-DMAC10.html) |
| MX (1) | MXPA00010241A (cg-RX-API-DMAC10.html) |
| PT (1) | PT1079805E (cg-RX-API-DMAC10.html) |
| WO (1) | WO1999055306A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8110218B2 (en) | 2000-11-30 | 2012-02-07 | The Research Foundation Of State University Of New York | Compositions and methods for less immunogenic protein-lipid complexes |
| US20020132982A1 (en) * | 2000-11-30 | 2002-09-19 | Balasubramanian Sathyamangalam V. | AHF associated dispersion system and method for preparation |
| US7625584B2 (en) * | 2000-11-30 | 2009-12-01 | The Research Foundation Of State University Of New York | Method of complexing a protein by the use of a dispersed system and proteins thereof |
| DE60335469D1 (de) * | 2002-07-02 | 2011-02-03 | Univ Texas | Radioaktiv markierte verbindungen und liposome und ihre herstellungs- und anwendungsverfahren |
| US7351688B2 (en) * | 2003-02-05 | 2008-04-01 | The Research Foundation Of State University Of New York | Compositions and methods for less immunogenic protein formulations |
| PT1633440E (pt) * | 2003-04-15 | 2008-08-25 | Opperbas Holding Bv | Composição farmacêutica que compreende proteínas e/ou polipéptidos e partículas coloidais |
| WO2005017526A1 (en) * | 2003-08-05 | 2005-02-24 | The Research Foundation Of State University Of New York | Reconstitution medium for protein and peptide formulations |
| US20070003607A1 (en) * | 2003-09-02 | 2007-01-04 | Vibhudutta Awasthi | Neutral liposome-encapsulated compounds and methods of making and using thereof |
| US7208174B2 (en) * | 2003-12-18 | 2007-04-24 | Hoffmann-La Roche Inc. | Liposome compositions |
| PL1713446T3 (pl) * | 2004-01-23 | 2011-05-31 | Camurus Ab | Nielamelarne trójskładnikowe kompozycje lipidów |
| DK2371856T3 (en) | 2004-11-12 | 2022-08-08 | Bayer Healthcare Llc | Site-directed modifikation af FVIII |
| US8895717B2 (en) * | 2005-04-15 | 2014-11-25 | The Board Of Regents Of The University Of Texas System | Delivery of siRNA by neutral lipid compositions |
| BRPI0612843A2 (pt) * | 2005-06-29 | 2010-11-30 | The Research Foundation Of State University Of New York | composição farmacêutica, métodos para fabricar a composição, e, uso de uma formulação |
| WO2007021822A2 (en) * | 2005-08-09 | 2007-02-22 | The Research Foundation Of State Of University Of New York At Buffalo | Compositions and methods of preparation of liposomal microparticulate il-12 |
| EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| US7875288B2 (en) * | 2006-03-30 | 2011-01-25 | The Research Foundation Of State University Of New York | Method for treating blood coagulation disorders |
| EP2007357B1 (en) * | 2006-03-30 | 2016-11-09 | The Research Foundation Of State University Of New York | Compositions of less immunogenic and long-circulating protein-lipid complexes |
| DK2101821T3 (da) * | 2006-12-15 | 2014-10-06 | Baxter Healthcare Sa | Faktor VIIA-(poly)sialinsyre-konjugat med forlænget halveringstid in vivo |
| WO2008077616A1 (en) | 2006-12-22 | 2008-07-03 | Csl Behring Gmbh | Modified coagulation factors with prolonged in vivo half-life |
| EP2865760B1 (en) | 2008-06-24 | 2017-10-11 | CSL Behring GmbH | Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life |
| EP2299953B1 (en) | 2008-07-14 | 2017-04-12 | Polypid Ltd. | Sustained-release drug carrier composition |
| WO2010135714A2 (en) | 2009-05-22 | 2010-11-25 | The Methodist Hospital Research Institute | Methods for modulating adipocyte expression using microrna compositions |
| CN102470105B (zh) | 2009-07-14 | 2015-07-29 | 波利皮得有限公司 | 持续释放药物载体组合物 |
| US10058837B2 (en) | 2009-08-28 | 2018-08-28 | The Trustees Of Columbia University In The City Of New York | Systems, methods, and devices for production of gas-filled microbubbles |
| US20130028959A1 (en) | 2009-12-16 | 2013-01-31 | Massachusetts Institute Of Technology | Liposomes for Preventing the Spread of HIV |
| EP2512588A4 (en) | 2009-12-16 | 2014-06-04 | Univ Columbia | METHODS, DEVICES AND SYSTEMS FOR ULTRASOUND-RELEASED ON-DEMAND AGGREGATE FREEZING |
| JP5860409B2 (ja) | 2010-01-19 | 2016-02-16 | ポリピッド リミテッド | 徐放性核酸マトリックス組成物 |
| US8637448B2 (en) | 2010-09-14 | 2014-01-28 | University Of Rochester | Recombinant factor VIII having enhanced stability following mutation at the A1-C2 domain interface |
| DE102010043733A1 (de) | 2010-11-10 | 2012-05-10 | Oxprotect Gmbh | Unbeladene PEGylierte Liposomen zur Verwendung als Arzneimittel zur Prophylaxe und Therapie von hämorrhagischen und thrombo- embolischen Erkrankungen |
| US9458223B2 (en) | 2012-02-15 | 2016-10-04 | Csl Behring Gmbh | Von willebrand factor variants having improved factor VIII binding affinity |
| EP2796145B1 (en) | 2013-04-22 | 2017-11-01 | CSL Ltd. | A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge |
| DK3164150T3 (da) | 2014-07-02 | 2021-02-08 | CSL Behring Lengnau AG | Modificeret von willebrand-faktor |
| GB201417589D0 (en) | 2014-10-06 | 2014-11-19 | Cantab Biopharmaceuticals Patents Ltd | Pharmaceutical Formulations |
| SG11201706659WA (en) | 2015-03-06 | 2017-09-28 | Csl Behring Recombinant Facility Ag | Modified von willebrand factor having improved half-life |
| CA2986625A1 (en) | 2015-05-22 | 2016-12-01 | Csl Behring Recombinant Facility Ag | Methods for preparing modified von willebrand factor |
| CA2986626A1 (en) | 2015-05-22 | 2016-12-01 | Csl Behring Recombinant Facility Ag | Truncated von willebrand factor polypeptides for treating hemophilia |
| GB201518170D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent |
| GB201518171D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for topical administration with therapeutic agent |
| GB201518172D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for use in medicine |
| SG11201805494WA (en) | 2016-01-07 | 2018-07-30 | Csl Behring Recombinant Facility Ag | Mutated von willebrand factor |
| AU2017204955B2 (en) | 2016-01-07 | 2021-04-01 | CSL Behring Lengnau AG | Mutated truncated von Willebrand Factor |
| WO2017220099A1 (en) | 2016-06-24 | 2017-12-28 | Statens Serum Institut | Adjuvants with modified drainage properties |
| WO2018005657A1 (en) | 2016-06-28 | 2018-01-04 | Verily Life Sciences Llc | Serial filtration to generate small cholesterol-containing liposomes |
| DK3538133T3 (da) | 2016-11-11 | 2021-04-19 | CSL Behring Lengnau AG | Trunkeret von willebrand faktor polypeptider til behandling af hæmofili |
| JP2020504082A (ja) | 2016-11-11 | 2020-02-06 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | 血液凝固障害の処置又は予防における血管外投与のための切断型フォン・ヴィルブランド因子ポリペプチド |
| GB202111757D0 (en) * | 2021-08-17 | 2021-09-29 | Cantab Biopharmaceuticals Patents Ltd | Modified colloidal particles for use in the treatment of haemophilia A |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7900459A (nl) | 1979-01-19 | 1980-07-22 | Hendrik Coenraad Hemker Prof D | Farmaceutisch preparaat en werkwijze ter bereiding daarvan. |
| JPS56127307A (en) * | 1980-03-11 | 1981-10-06 | Green Cross Corp:The | Blood-coagulation factor 8 pharmaceutical for oral administration |
| US4348384A (en) | 1980-10-17 | 1982-09-07 | Dainippon Pharmaceutical Co., Ltd. | Pharmaceutical composition for oral administration containing coagulation factor VIII or IX |
| US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5527528A (en) * | 1989-10-20 | 1996-06-18 | Sequus Pharmaceuticals, Inc. | Solid-tumor treatment method |
| WO1991012021A2 (en) * | 1990-02-13 | 1991-08-22 | Oxford Virology Plc | Therapeutic agents, and intermediates for the synthesis thereof |
| US6326353B1 (en) * | 1993-03-23 | 2001-12-04 | Sequus Pharmaceuticals, Inc. | Enhanced circulation effector composition and method |
-
1999
- 1999-04-23 CA CA002329768A patent/CA2329768C/en not_active Expired - Fee Related
- 1999-04-23 US US09/673,412 patent/US6593294B1/en not_active Expired - Lifetime
- 1999-04-23 EP EP99916022A patent/EP1079805B1/en not_active Expired - Lifetime
- 1999-04-23 BR BR9909978-0A patent/BR9909978A/pt not_active Application Discontinuation
- 1999-04-23 ES ES99916022T patent/ES2233036T3/es not_active Expired - Lifetime
- 1999-04-23 DE DE69922189T patent/DE69922189T2/de not_active Expired - Lifetime
- 1999-04-23 AT AT99916022T patent/ATE283034T1/de active
- 1999-04-23 PT PT99916022T patent/PT1079805E/pt unknown
- 1999-04-23 JP JP2000545506A patent/JP4545928B2/ja not_active Expired - Fee Related
- 1999-04-23 AU AU34414/99A patent/AU747391B2/en not_active Ceased
- 1999-04-23 MX MXPA00010241A patent/MXPA00010241A/es active IP Right Grant
- 1999-04-23 WO PCT/IL1999/000217 patent/WO1999055306A1/en not_active Ceased
-
2002
- 2002-12-26 US US10/327,970 patent/US6930087B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4545928B2 (ja) | 第ｖｉｉｉ因子及び中性リポソームを含有する薬学的組成物 | |
| AU692460B2 (en) | Bioadhesive emulsion preparations for enhanced drug delivery | |
| CA2784394C (en) | Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof | |
| Qin et al. | Challenges and strategies to enhance the systemic absorption of inhaled peptides and proteins | |
| Zhang et al. | Nanoparticulate systems for growth factor delivery | |
| Rogers et al. | The potential of liposomes in oral drug delivery | |
| JP4728580B2 (ja) | 製剤 | |
| JP2022101576A (ja) | スギ花粉エピトープを封入するｔｉｍｐ（組織性メタロプロテアーゼ阻害因子） | |
| US8377885B2 (en) | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof | |
| EP0460100A1 (en) | Liposome gel composition and method | |
| KR20010021911A (ko) | 구강내에서의 약제의 제어방출용 탄닌산-중합체 조성물 | |
| JP2001513544A (ja) | 脂質含有組成物及びこれらの使用 | |
| Torchilin | Affinity liposomes in vivo: factors influencing target accumulation | |
| JPH11507628A (ja) | 改良されたリポソーム製剤 | |
| JP3926626B2 (ja) | 免疫学的寛容−誘導物質 | |
| JP2010518012A (ja) | カンプトテシン誘導体を含む医薬組成物 | |
| Malmsten | Block copolymers in pharmaceutics | |
| Rogachev et al. | Permeation of nanoparticles into pulmonary surfactant monolayer: in situ X-ray standing wave studies | |
| Kenny et al. | Proteins of the kidney microvillar membrane. Reconstitution of endopeptidase in liposomes shows that it is a short-stalked protein | |
| JP2005529086A (ja) | 精製大豆ホスファチジルセリンによって作製される渦巻状物 | |
| CN1774281B (zh) | 包含蛋白质和/或多肽以及胶体颗粒的药物组合物 | |
| JP3898783B2 (ja) | 生体内分解性ヒアルロン酸架橋ゲル組成物及び生体内分解性ヒアルロン酸架橋ゲル製剤 | |
| HRP20230985T1 (hr) | Farmaceutske formulacije pegiliranih liposoma i faktora koagulacije krvi | |
| USRE49251E1 (en) | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof | |
| JP2817883B2 (ja) | 高度に完全なリポソームおよびその製剤法と用途 |